Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's...
-
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Investigative Site Network Market Size, Share & Trends Analysis Report by Therapeutic Areas (Oncology, Cardiology), Phase (Phase I,...
-
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's...
-
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Cancer cells sometimes find ways to...
-
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Gallbladder Cancer - Global Clinical Trials Review, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial...
-
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Apoptosis Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's...
-
Dublin, Dec. 20, 2023 (GLOBE NEWSWIRE) -- The "Pediatric Clinical Trials Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The pediatric clinical trials...
-
Dublin, July 26, 2022 (GLOBE NEWSWIRE) -- The "DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. DNA Damage Response (DDR)...
-
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immune-checkpoint Drugs in Oncology:...
-
Dublin, May 11, 2022 (GLOBE NEWSWIRE) -- The "Oncolytic Virotherapies: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Oncolytic Virotherapies: Analytical Tool is the...